Iovance Biotherapeutics: High-Risk Cancer Stock Potential
A bold, high‑risk biotech bet can pay off with patience and discipline. This article breaks down iovance biotherapeut...
Compare which total market fund to hold in retirement in 2024 and how to balance it with other assets. Focus on cost, tax efficiency, and diversification.
28,509 articlesA bold, high‑risk biotech bet can pay off with patience and discipline. This article breaks down iovance biotherapeut...
If SpaceX shifts a sizable slice of its IPO to everyday investors, the market could see bigger demand and new pricing...
3D Systems' Q1 2026 update sheds light on demand, margins, and cash flow across its printing systems, materials, and ...
Illinois embeds a first-of-its-kind 0.2% tax on digital asset activity in its $55.9 billion budget, set to take effec...
Mega-cap leadership keeps steering the bull market. AIC rally and AI-driven spend lift MGK, SCHG, and IWF as investor...
SpaceX has filed its S-1 to go public, presenting a three-pronged business plan that could fund a city on Mars. Here ...
Fundstrat’s Granny Shots ETF outperforms the S&P 500 through mid-2026, fueling debate as Tom Lee raises the odds of a...
A notable fund just built a fresh position in a cloud security leader. Discover the numbers behind winmill loads qual...
Fidelity’s Emerging Markets ETF has surged about 30% year-to-date, driven by chipmakers and Chinese tech names, yet r...
A solid move by a seasoned fund—Alpine Capital Research increases its Arrow Electronics position. Learn what this cou...
As enterprise cybersecurity budgets surge toward $215B by 2026, three ETFs stand out by delivering broad, full-stack ...
A bold new plan could reshape crypto funding: a $300 million preferred stock sale to back an ETH-heavy treasury built...